LETTER TO THE EDITOR

Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease

Dongsheng Li1†, Gangan Yan2†, Wenwen Zhou1, Shuyi Si1, Xiaoping Liu2, Jing Zhang1*, Yan Li1* and Yunyu Chen2*

Abstract

Because of the emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different regions of the world, the battle with infectious coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has been seesawing. Therefore, the identification of antiviral drugs is of particular importance. In order to rapidly identify inhibitors for SARS-CoV-2 3-chymotrypsin-like protease (3CLpro), an enzyme essential for viral replication, we combined the fluorescence polarization (FP) technique with biotin-avidin system (BAS) and developed a novel sandwich-like FP screening assay. Through high-throughput screening, two hits of 3CLpro inhibitors, ginkgolic acid (GA) and anacardic acid (AA) were identified, which showed IC50 values of 11.29 ± 0.48 and 12.19 ± 0.50 μM, respectively. Their binding modes were evaluated by HPLC-Q-TOF–MS. There was no mass increase detected for SARS-CoV-2 3CLpro incubated with either GA or AA, indicating the absence of covalent adducts. The kinetic analysis clearly demonstrated that both GA and AA inhibit SARS-CoV-2 3CLpro via reversible and mixed-inhibition manner. Our results argue against conclusion that GA and AA act as irreversible and covalent inhibitors against SARS-CoV-2 3CLpro, which is based on the studies by Chen et al.

Keywords: SARS-CoV-2, 3CL protease inhibitor, Non-covalent, Reversible, Mixed-inhibition manner, Ginkgolic acid, Anacardic acid

Dear Editor,

Although much progress has been made in the surveillance and control of coronavirus disease 2019 (COVID-19) pandemic around the world since its outbreak in 2019, the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been undergoing mutations continuously, raising the concerns that the SARS-CoV-2 variants may gain resistance to the current SARS-CoV-2 neutralizing antibodies, vaccines, RNA-dependent RNA polymerase (RdRp) inhibitors and 3-chymotrypsin-like protease or main protease (3CLpro or Mpro) inhibitors [1–4]. If nothing else, SARS-CoV-2 has taught us that widespread proliferation, low fidelity genome synthesis, and selective pressure will quickly produce drug resistant phenotypes [3]. Therefore, there is still an urgent need to develop safe, effective, and affordable prevention/treatment agents for SARS-CoV-2 infection and future drug-resistance.

Several viral proteins, including 3CLpro, Papain-like protease (PLpro) and RdRp have been prioritized as...
promising anti-COVID-19 drug targets. Among the three viral proteases, 3CL\textsuperscript{pro} appears to be a high-profile drug target for the development of broad-spectrum antivirals: first, 3CL\textsuperscript{pro} plays an essential role in coronavirus replication by cleaving the viral polyproteins at more than 11 sites; second, 3CL\textsuperscript{pro}s have relatively high sequence similarity within each CoV group; moreover, 3CL\textsuperscript{pro} has an unique substrate preference for glutamine at the P1 site (Leu-Gln|Ser,Ala,Gly)), a feature that is absent in closely related host proteases; last but not least, up to now, none of the 25 most common 3CL\textsuperscript{pro} mutants involve residues in the active site or at the dimerization interface [3]. Even with several exceptions, including P132H, the resulting amino acid is often similar in size and physicochemical properties, such as K→R, which does not compromise small-molecule drug inhibition [3]. Therefore, it is feasible to design 3CL\textsuperscript{pro} inhibitors with high selectivity and high potential to monitor drug-resistance. Our primary goal was to identify lead compounds targeting SARS-CoV-2 3CL\textsuperscript{pro} using our newly established sandwich-like FP screening assay [5]. Among 3000 tested compounds, ginkgolic acid (GA) and anacardic acid (AA) displayed the most potent inhibitory effects on the hydrolytic activity of SARS-CoV-2 3CL\textsuperscript{pro}. As illustrated in Fig. 1a, SARS-CoV-2 3CL\textsuperscript{pro} was inhibited by GA in a dose-dependent manner, with half maximal inhibitory concentration (IC\textsubscript{50}) value of 11.29 ± 0.48 μM. The IC\textsubscript{50} value of AA against SARS-CoV-2 3CL\textsuperscript{pro} was 12.19 ± 0.50 μM (Fig. 1b), showing similar inhibitory efficiency as GA. Subsequently, we confirmed the proteolytic inhibition of GA and AA against 3CL\textsuperscript{pro} using fluorescence resonance energy transfer (FRET) assay. The IC\textsubscript{50} values of GA and AA towards 3CL\textsuperscript{pro} were 4.89 ± 0.30 μM (Fig. 1c) and 7.60 ± 0.30 μM (Fig. 1d), respectively, which were similar to the previously published results [6, 7].

Covalent inhibitors usually use electrophilic moieties, prominently nitrile, disulfide or cyanoacrylate to react with a corresponding site in its target [8]. The majority of current reported SARS-CoV-2 3CL\textsuperscript{pro} inhibitors are peptidomimetic covalent inhibitors with a reactive warhead such as ketone, aldehyde or ketoamide [9]. A highlighting milestone is Nirmatrelvir (PF-07321332), a covalent inhibitor carrying a nitrile warhead that targets SARS-CoV-2 3CL\textsuperscript{pro}, which plus Ritonavir has received its first conditional authorization on 31 December 2021 for the treatment of COVID-19 in the United Kingdom [10]. Nirmatrelvir has also been authorized for emergency use in the USA (December 2021), and more recently received a conditional authorization in the EU (January 2022). Inspired by this fact, we used PF-07321332 as a positive control to demonstrate that the covalent conjugate can be detected by our developed mass spectrum assay. Notably, the presence of a mass shift of 500 Da after treatment with PF-07321332 indicated a covalent adduct formation (Fig. 1e), in agreement with the results presented in the previous study [10]. Considering the lack of reactive group in GA and AA, covalent inhibition against 3CL\textsuperscript{pro} is usually unlikely. To test this idea, we compared the molecular weights of 3CL\textsuperscript{pro} before and after its incubation with GA or AA using HPLC-Q-TOF–MS. A MS peak with a mass value of 34,863.01 Da (Fig. 1f)/34,862.24 Da (Fig. 1g) was detected for SARS-CoV-2 3CL\textsuperscript{pro} incubated with GA or AA, respectively. These numbers were equal to the molecular weight of SARS-CoV-2 3CL\textsuperscript{pro} alone (34,864.15 Da) (Fig. 1f, g), indicating non-covalent conjugation with either GA or AA. In conclusion, our results suggested that neither GA nor AA covalently reacted with SARS-CoV-2 3CL\textsuperscript{pro}.

To further understand the nature of non-covalent interaction between SARS-CoV-2 3CL\textsuperscript{pro} and GA or AA at the molecular level, surface plasmon resonance (SPR)-based
binding assay was used to measure the affinity constant and characterize these interactions. Although GA could increase the real refractive index unit (RIU) response of SARS-CoV-2 3CLpro in a dose-dependent manner, the $K_D$ was $4.77 \times 10^{-3}$ M (Fig. 1h), indicating poor affinity and reversible binding mode between GA and SARS-CoV-2 3CLpro. Very similar results were obtained regarding the binding of AA to SARS-CoV-2 3CLpro with $K_D$ of $6.21 \times 10^{-3}$ M (Fig. 1i). Meanwhile, both GA and AA exhibited fast association rate ($k_a$) and fast dissociation rate ($k_d$) values in binding kinetics curves (Fig. 1h, i).

It is well documented that reversible inhibitors bind to enzymes by non-covalent bonds. The non-covalent adduct formation between SARS-CoV-2 3CLpro and
GA or AA indicated that GA and AA are likely to exert inhibitory effects via reversible inhibition. Therefore, kinetic analysis was performed to investigate the inhibitory mechanisms of GA and AA using FRET assay. Based on enzyme kinetics analysis, the slopes and intercepts of the reciprocal Lineweaver–Burk plots elevated with the increase in inhibitor concentration, which is inconsistent with the three main types of inhibition, competitive, non-competitive, or uncompetitive (Fig. 1j, l). The intersection of each trend line in the second quadrant suggested a mixed-type inhibitory mode, implying that these agents may bind this target enzyme at both catalytic active site and non-catalytic site. The inhibitory constant (Ki) values of GA and AA were 1.69 and 1.87 μM, respectively (Fig. 1k, m). Overall, these results suggested that GA and AA act as reversible and mixed-type inhibitors against SARS-CoV-2 3CLpro, which is supported by the previous finding [6].

In summary, our data provide insights into the binding modes between SARS-CoV-2 3CLpro and GA or AA, which is non-covalent, reversible and mixed-type of inhibition. Our results are inconsistent with a previously report about the covalent binding between SARS-CoV-2 3CLpro and GA or AA [7]. Regardless, these compounds are promising candidates worthy of structure modification for the treatment of COVID-19.

Acknowledgements
We are grateful to senior engineer Zhensheng Xie (Institute of Biophysics, Chinese Academy of Sciences, Beijing, China) for her kind help in HPLC-Q-TOF-MS analysis. We sincerely thank Professor Yanchang Wang (Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, United States), Dr. Xiaojun Wu (Department of Neurosciences, The University of Toledo, Toledo, OH, United States) and Dr. Jie Wang (Department of Dermatology, Center for Cutaneous Biology and Immunology Research, Henry Ford Health System, Detroit, MI, United States) for their insightful comments and reading of the manuscript.

Author contributions
DL, GY, WZ, SS, XL. JZ, YL, and YC conceived and designed the experiments. DL, GY, WZ, JZ, YL, and YC performed and analyzed the experiments. DL and GY wrote the manuscript. JZ, YL, and YC revised and polished the manuscript. All authors reviewed the results. All authors read and approved the final manuscript.

Funding
This work was supported by National Natural Science Foundation of China (Nos. 81370087, 81773784, 81703546), National Science Foundation of Anhui Province (No. 1808085QH265), University Natural Science Research Project of Anhui Province (KJ2019ZD30, KJ2021A0839, JS20210549); Key Technologies Research and Development Program of Anhui Province (No. 202004a07020041); CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-2M-1-054); and Young Talent Project of Wannan Medical College (No. wyqnyx202104).

Availability of data and materials
All data generated or analyzed during this study are included in this article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors approved for publication.

Competing interests
The authors declare no competing interests.

Received: 5 January 2022 Accepted: 1 May 2022
Published online: 19 May 2022

References
1. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elle. 2020;9:e61312.
2. Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2523.
3. Sacco MD, Hu Y, Gongora MV, Meilleur F, Kemp MT, Zhang X, et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022;32:498–500.
4. Vangeel L, Chiu W, De Jonghe S, Maes P, Slechtn B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.
5. Yan G, Li D, Lin Y, Fu Z, Qi H, Liu X, et al. Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. Cell Biosci. 2021;11(1):199.
6. Xiong Y, Zhu GH, Wang HH, Hu Q, Chen LL, Guan XQ, et al. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening. Fitoterapia. 2021;152:104909.
7. Chen Z, Cui Q, Cooper L, Zhang P, Lee H, Chen Z, et al. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell Biosci. 2021;11(1):45.
8. Lagouette R, Patouret R, Wnssinger N. Covalent inhibitors: an opportunity for rational target selectivity. Curr Opin Chem Biol. 2017;39:54–63.
9. Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, et al. Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J Am Chem Soc. 2021;143(49):20697–709.
10. Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2021. https://doi.org/10.1007/s13238-021-00883-2.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.